At PSYCH Symposium in the British Museum on 6 July a conversation between Professor Robin Carhart-Harris and journalist Kate Spicer explored the impact of psychedelic research...
In what marks a positive development for patient access to psychedelic therapies in the US, the American Medical Association has released the language of its first-ever...
In light of clinical research showing MDMA-assisted therapy as a potential treatment for PTSD, at PSYCH Symposium in the British Museum on 6 July a conversation...
At PSYCH Symposium in the British Museum on 6 July, the panel ‘Neuroimaging & Psychedelics: The Past, Present & Future’ explored how neuroimaging can inform our...
PSYCH Symposium’s afternoon panels saw discussions continue the exploration of the landscape of psychedelic healthcare.
PSYCH Symposium returned at the British Museum on 6 July to explore how psychedelic medicines can innovate healthcare – from mental health to eating disorders and...
PSYCH Symposium: London 2023 brought together key stakeholders to explore the landscape of psychedelic medicine at the British Museum on Thursday, 6 July.
Psychedelic Medicine Investment Fund Negev Capital is aiming to innovate mental healthcare in Europe by providing funding to companies on the cutting edge of psychedelic research.
Awakn Life Sciences has completed the sale of Awakn London Limited Ltd.,
PSYCH Symposium is returning at the British Museum on 6 July, when a panel of experts will discuss how psychedelics could innovate eating disorder care.
CEO of Cybin Inc.
Authorised psychiatrists are now able to prescribe MDMA and psilocybin for PTSD and treatment-resistant depression, respectively, from 1 July.
